Author:
Taylor Carly,Loukas Vanessa,Muwonge Jasmine,Taylor Jessica L.,Boyle Joseph
Abstract
Introduction
Extended-release subcutaneous buprenorphine is an increasingly common treatment for opioid use disorder. Serious adverse events are rare and may be poorly understood. This report describes an early surgical intervention to address tissue necrosis resulting from misplaced subcutaneous buprenorphine injection. We review identifying characteristics that distinguish the necrotic reaction from other adverse effects of subcutaneous buprenorphine and offer guidance to continue treatment with subcutaneous buprenorphine.
Case Report
A 33-year-old patient returned to clinic within an hour of his buprenorphine injection, reporting pain and skin changes unlike his previous injections. Non blanching erythema consistent with early necrosis was evident, and the patient was referred for surgical removal of his buprenorphine depot. The patient had uncomplicated healing of the surgical site and was provided sublingual buprenorphine before returning to continue treatment with subcutaneous buprenorphine.
Discussion
Although skin necrosis is known to be a rare complication of subcutaneous buprenorphine injection, early surgical excision to limit injury has not been described. Signs and symptoms of skin necrosis must be better understood to facilitate early intervention and continued treatment.
Conclusions
This case affirms that a patient may continue treatment with subcutaneous buprenorphine despite suffering skin necrosis and demonstrates the value of early surgical intervention after superficial placement of extended-release buprenorphine.
Publisher
Ovid Technologies (Wolters Kluwer Health)
Reference7 articles.
1. Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial;Lancet,2019
2. Effects of monthly buprenorphine extended-release injections on patient-centered outcomes: a long-term study;J Subst Abuse Treat,2020
3. Economic evaluation of extended-release buprenorphine for persons with opioid use disorder;JAMA Netw Open,2023
4. Characterizing initiation, use, and discontinuation of extended-release buprenorphine in a nationally representative United States commercially insured cohort;Drug Alcohol Depend,2021
5. Skin necrosis following inadvertent dermal injection of extended-release buprenorphine;J Addict Med,2022
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Buprenorphine;Reactions Weekly;2024-07-06